Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Dividend Re-investment (2009 Deferred Annual Bonus Plan) |
| Instrument | Ordinary Shares of 25 pence each |
| Transaction Date | July 14, 2016 |
| Share Price | £16.285 |
| Total Volume Acquired | 1,065.862 shares |
Material Changes
The filing reports an increase in the notional interest in Ordinary Shares for Ms. C Thomas, SVP of HR. This increase resulted from the re-investment of dividends paid on July 14, 2016. The transaction included both personal contributions and matching shares.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items related to the company's operations.
Investor Verification Points
- Verify the total number of shares acquired (1,065.862) and the split between personal contributions and matching shares.
- Confirm the transaction price of £16.285 aligns with the market price on July 14, 2016.
- Note that this filing is a regulatory disclosure of insider activity and does not reflect broader company financial performance.